Pages that link to "Q51982834"

The following pages link to Influence of CD4 CD25 regulatory T cells on low/high-avidity CD4 T cells following peptide vaccination (Q51982834):

Displaying 30 items.

• Antigen-specific active immunotherapy for ovarian cancer (Q24193567) (← links)
• Antigen-specific active immunotherapy for ovarian cancer (Q24240962) (← links)
• HLA‐F is a surface marker on activated lymphocytes (Q24300864) (← links)
• Narrowing the Gap: Preserving Repertoire Diversity Despite Clonal Selection during the CD4 T Cell Response (Q26796086) (← links)
• Effective T helper cell responses against retroviruses: are all clonotypes equal? (Q26995251) (← links)
• Apoptosis of CD4( )CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2 (Q30439284) (← links)
• Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity (Q33311675) (← links)
• Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells (Q33496761) (← links)
• Split T cell tolerance against a self/tumor antigen: spontaneous CD4 but not CD8 T cell responses against p53 in cancer patients and healthy donors (Q33999909) (← links)
• LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. (Q34111719) (← links)
• NY-ESO-1: review of an immunogenic tumor antigen (Q34550142) (← links)
• MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells (Q35058966) (← links)
• Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma (Q35218562) (← links)
• Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer (Q35921697) (← links)
• Immunopathogenesis of multiple sclerosis (Q36832873) (← links)
• Mobilizing the low-avidity T cell repertoire to kill tumors (Q36891310) (← links)
• Anti-CCR4 mAb selectively depletes effector-type FoxP3 CD4 regulatory T cells, evoking antitumor immune responses in humans. (Q37276644) (← links)
• Enhancement of tumor-reactive cytotoxic CD4 T cell responses after ipilimumab treatment in four advanced melanoma patients (Q37430286) (← links)
• FOXP3 Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. (Q38327236) (← links)
• Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy (Q39776358) (← links)
• HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties (Q39792286) (← links)
• Tumor-reactive CD8 T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival (Q39804019) (← links)
• Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8 T cells (Q40010912) (← links)
• Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells (Q43698125) (← links)
• Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. (Q45883472) (← links)
• NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells (Q49479838) (← links)
• Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes (Q50912428) (← links)
• NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer (Q51065844) (← links)
• Antigen-specific active immunotherapy for ovarian cancer (Q57688794) (← links)
• The opposing roles of CD4 T cells in anti-tumour immunity (Q88489714) (← links)